The Japanese encephalitis virus (JEV), an arthropod-born Flavivirus, is the major cause of viral encephalitis, responsible for 10,000-15,000 deaths each year, yet is a neglected tropical disease. Since the JEV distribution area has been large and continuously extending toward new Asian and Australasian regions, it is considered an emerging and reemerging pathogen. Despite large effective immunization campaigns, Japanese encephalitis remains a disease of global health concern. JEV zoonotic transmission cycles may be either wild or domestic: the first involves wading birds as wild amplifying hosts; the second involves pigs as the main domestic amplifying hosts. Culex mosquito species, especially Cx. tritaeniorhynchus, are the main competent vectors. Although five JEV genotypes circulate, neither clear-cut genotype-phenotype relationship nor clear variations in genotype fitness to hosts or vectors have been identified. Instead, the molecular epidemiology appears highly dependent on vectors, hosts' biology, and on a set of environmental factors. At global scale, climate, land cover, and land use, otherwise strongly dependent on human activities, affect the abundance of JEV vectors, and of wild and domestic hosts. Chiefly, the increase of rice-cultivated surface, intensively used by wading birds, and of pig production in Asia has provided a high availability of resources to mosquito vectors, enhancing the JEV maintenance, amplification, and transmission. At fine scale, the characteristics (density, size, spatial arrangement) of three landscape elements (paddy fields, pig farms, human habitations) facilitate or impede movement of vectors, then determine how the JEV interacts with hosts and vectors and ultimately the infection risk to humans. If the JEV is introduced in a favorable landscape, either by live infected animals or by vectors, then the virus can emerge and become a major threat for human health. Multidisciplinary research is essential to shed light on the biological mechanisms involved in the emergence, spread, reemergence, and genotypic changes of JEV.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3772072PMC
http://dx.doi.org/10.1371/journal.pntd.0002208DOI Listing

Publication Analysis

Top Keywords

japanese encephalitis
12
jev
9
encephalitis virus
8
wild domestic
8
wading birds
8
amplifying hosts
8
vectors
8
hosts vectors
8
hosts
5
review climate
4

Similar Publications

Background: Japanese encephalitis (JE) induced by Japanese encephalitis virus (JEV) infection is the most prevalent diagnosed epidemic viral encephalitis globally. The underlying pathological mechanisms remain largely unknown. Given that viruses are obligate intracellular parasites, cellular metabolic reprogramming triggered by viral infection is intricately related to the establishment of infection and progression of disease.

View Article and Find Full Text PDF

Development of nucleic acid-based vaccines against dengue and other mosquito-borne flaviviruses: the past, present, and future.

Front Immunol

January 2025

Infectious Disease Research Department, King Abdullah International Medical Research Center, King Saud bin Abdulaziz University of Health Sciences, Ministry of National Guard Health Affairs, Riyadh, Saudi Arabia.

Due to their widespread geographic distribution and frequent outbreaks, mosquito-borne flaviviruses, such as DENV (DENV), Zika virus (ZIKV), Japanese encephalitis virus (JEV), yellow fever virus (YFV), and West Nile virus (WNV), are considered significant global public health threats and contribute to dramatic socioeconomic imbalances worldwide. The global prevalence of these viruses is largely driven by extensive international travels and ecological disruptions that create favorable conditions for the breeding of and species, the mosquito vectors responsible for the spread of these pathogens. Currently, vaccines are available for only DENV, YFV, and JEV, but these face several challenges, including safety concerns, lengthy production processes, and logistical difficulties in distribution, especially in resource-limited regions, highlighting the urgent need for innovative vaccine approaches.

View Article and Find Full Text PDF

Emergence of locally acquired Japanese encephalitis virus in Australia, January 2021-June 2022: a national case series.

Commun Dis Intell (2018)

January 2025

Health Protection Policy and Surveillance Division, Australian Government Department of Health and Aged Care, Canberra, Australian Capital Territory, Australia.

Background And Methods: In March 2022, an outbreak of Japanese encephalitis virus (JEV) infection was identified in temperate south-eastern Australia, with detections in humans and animals. The unexpected emergence of JEV prompted a national public health response and a Communicable Disease Incident of National Significance was declared. JEV has previously only been identified in tropical north-eastern Australia in localised outbreaks.

View Article and Find Full Text PDF

The detection of Japanese encephalitis virus (JEV) in the Murray region, New South Wales: a public health investigation.

Commun Dis Intell (2018)

January 2025

Murrumbidgee and Southern New South Wales Local Health District, Public Health Unit, Infectious Diseases, NSW Health.

The detection of Japanese encephalitis virus (JEV) in pigs, at four piggeries in the Murray region in February 2022, prompted a public health investigation (PHI) by the New South Wales Department of Health (NSW Health) to identify people at greatest risk of infection. The PHI included three components: a vaccination clinic and accompanying clinic questionnaire; a serological investigation; and a cross-sectional study for consenting Australian-born participants who completed an extended questionnaire after receiving their serological results. The goals were to vaccinate a presumably naïve population to reduce associated risk and to understand the seroprevalence among Australian-born piggery workers.

View Article and Find Full Text PDF

Background: Japanese encephalitis virus (JEV) is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond five years remain limited.

Methods: We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!